Drug Information Association Logo
Corporate Tagline

Information Day on the New Identification of Medicinal Products (IDMP) International Standards and ICH M5/M2

Dec 4 2012 8:45AM - Dec 4 2012 5:00PM | European Medicines Agency Canary Wharf, 7 Westferry Circus London E14 4HB United Kingdom

« Back to Listing

Overview 

The five new International Identification of Medicinal Product (IDMP) standards are expected to be finalised and published by the International Organization of Standardisation (ISO) by the end of 2012. Implementation of these standards in the area of pharmacovigilance is further defined in the Commission Implementing Regulation (EU) 520/2012. The IDMP standards were developed in response to a worldwide demand for internationally harmonised specifications for exchanging medicinal product information in a robust and reliable manner. IDMP is one of a group of five standards, which together provide the basis for the unique identification of medicinal products.

The IDMP standards support the regulation of medicines and pharmacovigilance including Individual Case Safety Reports (ICSR). IDMP supports the activities of medicines regulatory agencies worldwide by jurisdiction.

Furthermore, under eHealth Governance Initiative (eHGI) semantic and technical interoperability has been identified as a key priority for modern healthcare delivery.

In the context of the international harmonisation activities, ICH is aiming to reach step 2 for public consultation of the M5 IDMP Implementation Guide (IG) in the next months. As per agreement with the ICH Steering Committee, the electronic submission of information on medicinal products and substances will be based on the Health Level 7 (HL7) Structured Product Labeling (SPL) IDMP messaging format, a major step forward in the international harmonization activities.

The course will provide important news on the eHealth Network activities and the challenges in semantic and technical interoperability of information on medicinal products. Data elements and message specifications as well as definitions of concepts for key terminologies in accordance with the ICH M5 IG will be further explained. The use of HL7 SPL IDMP Common Message Element Types (CMETs) will also be outlined in detail.

Furthermore, the Information Day will provide a forum to update stakeholders on the implementation activities in the context of the new pharmacovigilance legislation, more specifically, Article 57(2), second subparagraph of Regulation (EC) 726/2004. This will also include new aspects on maintenance of information on medicinal products.

Who Should Attend 

    • Regulatory affairs staff of pharmaceutical companies
    • Representatives of IT departments of medicines regulatory authorities, pharmaceutical companies and service providers
    • EU Qualified Persons responsible for Pharmacovigilance (EU QPPVs)
    • Pharmacovigilance staff of pharmaceutical companies and medicines regulatory authorities
    • Medicinal product management software vendors
    • Sponsors of clinical trials

     

    Learning Objectives 

    At the conclusion of this course participants should be able to:

    • Understand the ongoing international standardisation work on IDMP
    • Understand the e-health network activities and the ongoing work towards addressing interoperability challenges related to medicines
    • Recognise the main new features of the future IDMP messaging specifications
    • Prepare medicines regulatory authorities in the EU, IT vendors and pharmaceutical companies for the implementation of the new IDMP standards and adaptation of their regulatory product management and Pharmacovigilance systems
    • Understand the maintenance requirements for the electronic submission of medicinal product information by marketing authorisation holders, in compliance with the Article 57(2) provisions of Regulation (EC) 726/2004.

    Featured Topics 

    • e-health and interoperability challenges related to medicinal products
    • Key principles of the ICH M5 IDMP Implementation Guide
    • Use of HL7 SPL IDMP CMETs for the electronic exchange of information on medicinal products and substances
    • Article 57(2) and maintenance of information on medicinal products by marketing authorization holders
    • Questions and Answers on Article 57(2) implementation
    • Industry perspective on Article 57(2) and ISO IDMP standards implementation

    Contact Information 

    DIA Europe
    Kuechengasse 16, Postfach
    4002 Basel, Switzerland
    Phone: +41 61 225 51 51
    Fax: +41 61 225 51 52
    E-mail: diaeurope@diaeurope.org

    Hotel & Travel 

    Attendees have to make their own reservation.
    Recommended hotel close to the EMA:

    Hilton London Docklands Riverside
    265 Rotherhithe Street,
    London , SE16 5HW,
    United Kingdom

    Telephone: +44 (0)20 7231 1001
    Fax: +44 (0)20 7231 0599
    Email: reservations.docklands@hilton.com

    DIA was able to negotiate a special rate for a limited number of rooms:
    Room rate is GBP 145.00 per room incl. breakfast excl. VAT. Rooms are distributed on a first come, first serve basis.
    Please click here to book your accommodation and enter the corporate account number: 481223696. 

    The hotel is situated opposite of Canary Wharf conveniently connected by a
    shuttle boat. The landing stage is in walking distance to the EMA (2 min).

    Faculty 

    Previous Next

    Agenda  

    Day 1 Tuesday, December 04, 2012

    • 9:00AM - 9:45AM

      The Activities of the e-Health Network and initiatives in addressing technical and semantic interoperability related to medicines

      Speaker(s):

      • The Activities of the e-Health Network and initiatives in addressing technical and semantic interoperability related to medicines
        Rostislava Dimitrova
        Policy Officer
        European Comission, Belgium
    • 9:45AM - 10:30AM

      The Need for Standardisation in the Pharmaceutical Domain

      Speaker(s):

      • Electronic submission of information on medicines in the context of the new pharmacovigilance legislation in the EU
        Sabine Brosch, PharmD,PhD
        Business Lead, EudraVigilance and International Standardisation in PhV
        European Medicines Agency, European Union, United Kingdom
      • ISO Identification of Medicinal Products (IDMP) Implementation: FDA Perspective
        Vada A. Perkins, BSN,MSc,RN
        Senior Regulatory Program Management Officer, OD, CBER
        FDA, United States
      • Health Level Seven (HL7) Messaging Standards and their relationship in the Pharmaceutical and Healthcare Domains
        Vada A. Perkins, BSN,MSc,RN
        Senior Regulatory Program Management Officer, OD, CBER
        FDA, United States
    • 11:00AM - 12:30PM

      ISO IDMP Standards at a Glance

      Speaker(s):

      • Data elements and structures for unique identification and exchange of regulated medicinal product information (ISO 11615)
        Sabine Brosch, PharmD,PhD
        Business Lead, EudraVigilance and International Standardisation in PhV
        European Medicines Agency, European Union, United Kingdom
      • Data elements and structures for unique identification and exchange of regulated pharmaceutical product information (ISO 11616)
        Vada A. Perkins, BSN,MSc,RN
        Senior Regulatory Program Management Officer, OD, CBER
        FDA, United States
      • Data elements and structures for unique identification and exchange of regulated information on substances (ISO 11238)
        Ilaria Del Seppia
        European Medicines Agency, United Kingdom
    • 1:30PM - 2:00PM

      Status of the ICH M5 Harmonisation Work

      Speaker(s):

      • The achievements of the ICH M5 Expert Working Group and agreed next steps based on the recent face-to-face meeting held in November 2012 will be presented.
        Sabine Brosch, PharmD,PhD
        Business Lead, EudraVigilance and International Standardisation in PhV
        European Medicines Agency, European Union, United Kingdom
      • The achievements of the ICH M5 Expert Working Group and agreed next steps based on the recent face-to-face meeting held in November 2012 will be presented.
        Vada A. Perkins, BSN,MSc,RN
        Senior Regulatory Program Management Officer, OD, CBER
        FDA, United States
    • 2:00PM - 3:00PM

      Industry’s Perspective on the Implementation of Article 57(2) and SPL and Expectations from the Harmonisation Activities

      Speaker(s):

      • Industry Perspective on XEVMPD and IDMP
        John W. Kiser, MSc
        Senior Director, Regulatory Operations
        Abbvie, United States
      • Lessons from Art 57 – Considerations for IDMP
        Raun S. Kupiec, MS
        Head of Quality, Genzyme EMEA
        Genzyme Europe, Netherlands
    • 3:30PM - 4:30PM

      Article 57(2) Maintenance and Frequently Asked Questions

      Speaker(s):

      • Next steps towards maintenance of information of medicines in accordance with Article 57(2)
        Sabine Brosch, PharmD,PhD
        Business Lead, EudraVigilance and International Standardisation in PhV
        European Medicines Agency, European Union, United Kingdom
      • Article 57(2) - Frequently Asked Questions
        Ilaria Del Seppia
        European Medicines Agency, United Kingdom

    Registration Fees 

    Other Fees

    Academia
    €150.00
    Government (Full Time)
    €150.00
    Standard
    €300.00
    Register Online

    CANCELLATION POLICY: All cancellations must be made in writing and received at the DIA office five working days prior to the event start date. Full event cancellations are subject to an administrative fee:

    • Industry (Member/Non-member) = €200.00
    • Academia/Charitable/Government /Non-profit (Full-Time) (Member/Non-member) = €100.00
    • Tutorial cancellation: €50.00

    If you do not cancel five working days prior to the event start date and do not attend, you will be responsible for the full registration fee. DIA reserves the right to alter the venue and dates if necessary. If an event is cancelled DIA is not responsible for airfare, hotel or other costs incurred by registered attendees. Registered attendees are responsible for cancelling their own hotel and travel reservations.

    « Back to Listing Back To Top